logo
Iron overload and toxicity
Blood group genotyping
Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products
A retrospective case note review of deceased recipients of vCJD-implicated blood transfusions
Biochemical quality of the pharmaceutically licensed plasma OctaplasLG® after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time
Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG®
Pathogen reduction technology (Mirasol®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS
Consecutive national surveys of ABO-incompatible blood transfusion in Japan
Massive transfusion – evaluation of current clinical practice and outcome in two large teaching hospital trusts in Northern England
A randomized study of buffy coat platelets in platelet additive solution stored 1–5 versus 6–7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients
Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study
Duffy antigen expression on reticulocytes does not alter following blood loss in an autologous donation model
Extracellular 20S proteasomes accumulate in packed red blood cell units
Erythrocyte survival tests in cases of anti-AnWj antibodies
Addendum to Vox Sanguinis 2008, 95; 272–279
Diary of Events